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Alzheimer’s disease (AD), a progressive neurodegenera-Frances Davenport,4 Tamara Ratovitsky,4
tive disorder, is associated with several risk factors,Cristian-Mihail Prada,6 Grace Kim,4 Sophia Seekins,4
including age and inheritance. The majority of early-Debra Yager,6 Hilda H. Slunt,4 Rong Wang,7
onset cases of AD are inherited as autosomal dominantMary Seeger,8 Allan I. Levey,9 Samuel E. Gandy,8
disorders and cosegregate with mutations in the follow-Neal G. Copeland,10 Nancy A. Jenkins,10
ing: the presenilin 1 (PS1) gene on chromosome 14 (StDonald L. Price,1,2,3,4 Steven G. Younkin,5,6
George-Hyslop et al., 1992; Sherrington et al., 1995;and Sangram S. Sisodia,1,2,4
Alzheimer’s Disease Collaborative Group, 1995; Wasco1Department of Pathology
et al., 1995; Campion et al., 1995; Chapman et al., 1995;2Department of Neuroscience
Cruts et al., 1995; Boteva et al., 1996; Perez-Tur et al.,3Department of Neurology
1995); the presenilin 2 (PS2) gene on chromosome 14Neuropathology Laboratory
(Levy-Lahad et al., 1995a, 1995b; Rogaev et al., 1995);The Johns Hopkins University
and the amyloid precursor protein (APP) gene on chro-School of Medicine
mosome 21 (Goate et al., 1991; Chartier-Harlin et al.,Baltimore, Maryland 21205
1991; Naruse et al., 1991; Mullan et al., 1992; Hendriks5Department of Neuroscience
et al., 1992). Mutations in PS1 and PS2 are causative inCase Western Reserve University
z50% of pedigrees with early-onset FAD (Schellenberg,Cleveland, Ohio 44106
1995).6Mayo Clinic Jacksonville
The mechanism(s) by which FAD-linked mutations inJacksonville, Florida 32224
PS cause AD have not been defined. However, recent7Mass Spectrometry Laboratory
studies indicate that conditioned medium from fibro-The Rockefeller University
blasts or plasma of affected members of pedigrees withNew York, New York 10021
PS1/PS2-linked mutations show a highly significant in-8Department of Neurology and Neuroscience
crease in the ratio of Ab1–42(43)/Ab1–40 relative tounaf-Cornell University Medical College
fected family members (Scheuner et al., 1996). TheNew York, New York 10021
emerging view that Ab1–42(43) plays a critical role in9Department of Neurology
the pathogenesis of AD is supported by several linesEmory University School of Medicine
of evidence as follows: first, physical chemical studiesAtlanta, Georgia 30322
indicate that Ab1–42(43) nucleates rapidly and is more10Mammalian Genetics Laboratory
fibrillogenic than Ab1–40 (Burdick et al., 1992; Jarrett etABL-Basic Research Program
al., 1993; Jarrett and Lansbury, 1993); second, severalNCI-Frederick Cancer Research and Development
FAD-linked mutations in APP alter the processing ofFrederick, Maryland 21702
APP in cultured cells, leading to increased levels of
Ab1–42 in culture medium (eitherwith orwithout increas-
ing the levels of Ab1–40) (Cai et al., 1993; Citron et al.,
Summary 1992; Suzuki et al., 1994); third, Ab1–42 is the principal
component of amyloid deposits (Roher et al., 1993); and
Mutations in the presenilin 1 (PS1) and presenilin 2 fourth, immunocytochemical and biochemical studies
genes cosegregate with the majority of early-onset that document early and selective deposition of Ab1–
familial Alzheimer’s disease (FAD) pedigrees. We now 42(43) species in brains of patients with AD (Iwatsubo
document that theAb1–42(43)/Ab1–40 ratio in the con- et al., 1994; Gravina et al., 1995) and Down’s Syndrome
ditioned media of independent N2a cell lines express- (Iwatsubo et al., 1995; Lemere et al., 1996a). More re-
ing three FAD-linked PS1 variants is uniformly elevated cently, massive Ab42(43) deposits were demonstrated
relative to cells expressing similar levels of wild-type in the cerebral cortex and cerebellum of individuals with
PS1. Similarly, the Ab1–42(43)/Ab1–40 ratio is elevated a PS1-linked E280A mutation (Lemere et al., 1996b).
in the brains of young transgenic animals coexpress- To examine directly the effects of wild-type and mu-
ing a chimeric amyloid precursor protein (APP) and tant PS1 on the ratio of Ab peptide species, we quanti-
an FAD-linked PS1 variant compared with brains of fied the levels of secreted Ab1–42(43) and Ab1–40 in the
transgenic mice expressing APP alone or transgenic conditioned medium of stable mouse neuroblastoma
mice coexpressing wild-type human PS1 and APP. (N2a) cell lines that constitutively express human APP
These studies provide compelling support for the view in combination with wild-type PS1 or FAD-linked PS1
that one mechanism by which these mutant PS1 cause variants. We document that the ratios of Ab1–42(43)/
AD is by increasing the extracellular concentration of Ab1–40 in media of independent cell lines expressing
Ab peptides terminating at 42(43), species that foster different FAD-linked PS1 variants (i.e., A246E, M146L,
or DE9 variants) are uniformly elevated compared withAb deposition.
the Ab1–42(43)/Ab1–40 ratios in media from cells that
express essentially indistinguishable levels of wild-type
PS1. We extended these analyses to examine whether11 These authors contributed equally to this work.
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mutant PS1 influences Ab1–42(43) production in the 1A, lanes 10–14), aPS1Loop detected variable levels of
an z40 kDa PS1 E9 polypeptide, a variant that is not aCNS. We mated transgenic mice expressing either hu-
man PS1 (Hu PS1) or Hu PS1 harboring an FAD-linked substrate for endoproteolysis (Thinakaran et al., 1996),
and low levels of the z16 kDa mouse PS1 derivative.A246E mutation with transgenic mice expressing ele-
vated levels of chimeric murine (Mo/Hu) APP-695 har- Interestingly, the z16 kDa endogenous mouse PS1 de-
rivative failed to accumulate in cell lines expressing highboring a Hu Ab domain and mutations (K595N, M596L)
linked to Swedish FAD pedigrees (APPswe) (Mullan et levels of the M146L (line ML.10, Figure 1, lane 7), A246E
(line AE.29, lane 9), or DE9 (line DE9.18, lane 14) variants.al., 1992). We document that in the brains of young
transgenic animals coexpressing APPswe and mutant These results parallel our earlier demonstration that the
mouse z16 kDa PS1 derivative is undetectable in thePS1, the ratio of Ab1–42(43) to Ab1–40 is elevated as
compared with transgenic mice expressing APPswe brains of transgenic mice that overexpress human PS1
(Thinakaran et al., 1996), and appears to be replaced byalone or transgenic mice coexpressing Hu PS1and APP-
swe. Collectively, our studies of transfected cells and the human z17 kDa PS1 derivative.
In parallel, we examined the levels of N-terminal PS1,transgenic mice provide compelling support for the view
that mutant presenilin acquires property(ies) that influ- z27–28 kDa derivatives in the N2a lines using Ab14, a
polyclonal serum specific for amino acids 3–15 of humanence APP processing in a manner that results in elevated
extracellular concentrations of Ab1–42(43), a highly am- and mouse PS1 (Figure 1B). As expected, Ab14 detected
an z28 kDa N-terminal PS1 derivative in N2a cells ex-yloidogenic peptide that is selectively deposited in the
brains of individuals with AD and Down’s Syndrome pressing human APP alone (Figure 1B, lane 1) and z43
kDa and z27 kDa polypeptides, corresponding to full-(Iwatsubo et al., 1994; Gravina et al., 1995; Lemere et
al., 1996a). length human PS1 and an N-terminal human PS1 deriva-
tive, respectively, in N2a lines stably expressing human
wild-type PS1 (Figure 1B, lanes 2 and 3), M146L PS1
Results variant (Figure 1B, lanes 4–7), or A246E PS1 variant
(Figure 1B, lanes 8 and 9, respectively). As expected,
Expression of Human PS1 and APP in N2a Ab14 detected the z40 kDaPS1DE9 polypeptide in lines
Cell Lines expressing the DE9 PS1 variant and the endogenous
Stable mouse neuroblastoma (N2a) cell lines were gen- z28 kDa N-terminal derivative (Figure 1B, lanes 10–14).
erated that express the following: wild-type human APP In addition, the z28 kDa mouse N-terminal PS1 deriva-
alone (one line); human APP-695 with human wild-type tive failed to accumulate in cell lines expressing high
PS1 (two lines); and human APP-695 with three different levels of the M146L (Figure 1, lane 7), A246E (lane 9), or
FAD-linked PS1 variants (M146L [four lines], PS1 A246E the DE9 variant (lane 14), a result that mimicked the
[two lines], and PS1DE9 [five lines]). The steady-state compromised accumulation of the mouse z16 kDa
expression of APP and PS1 in each cell line was quanti- C-terminal derivative in these lines.
fied by Western blotting, [125I]protein A detection and To determine the steady-state levels of accumulated
phosphorimaging. APP in stable N2a lines, we used antibody CT15, a poly-
To examine PS1 expression, we used aPS1Loop, an clonal antiserum raised against the C-terminal 15 resi-
antiserum that specifically reacts with epitopes in the dues of APP (Sisodia et al., 1993). As expected, CT15
hydrophilic “loop” domain of PS1 (amino acids 263–407) reacted with low levels of mouse APP in untransfected
(Thinakaran et al., 1996). We recently reported that PS1 N2a cells (Figure 2, lane 1) and high, butvariable levels of
is subject to endoproteolytic processing in vivo, and the full-length z100 and 105 kDa polypeptides representing
preponderant PS1-related species that normally accu- synthetic and mature forms of human APP-695, respec-
mulate in cultured mammalian cells, and in the brains tively, in each of the cell lines (Figure 2). [35S]-methionine
of rodents, primates, and humans are z27–28 kDa pulse-labelling, immunoprecipitation, and phosphorim-
N-terminal and z16–17 kDa C-terminal derivatives (Thi- aging analysis revealed that relative biosynthetic rates
nakaran et al., 1996). In untransfected N2a cells (data of human APP in each of the lines were indistinguishable
not shown) and N2a cells expressing human APP alone from the steady-state analysis shown in Figure 2 (data
(Figure 1A, lane 1), aPS1Loop antiserum detected an not shown).
z16 kDa C-terminal PS1 derivative of mouse PS1. More-
over, and consistent with our earlier observations in
African monkey kidney COS-1 and human embryonic Ab in Conditioned Medium of Cell Lines
The levels of Ab1–40 and Ab1–42(43) species that accu-kidney 293 cells expressing human PS1 (Thinakaran et
al., 1996), aPS1Loop antiserum detected z43 kDa and mulated in the conditioned medium of N2a cells coex-
pressing human APP and human PS1 were quantifiedz17 kDa polypeptides, corresponding to full-length hu-
man PS1 and a C-terminal human PS1 derivative, re- using a well characterized BAN-50/BA-27 and BAN-50/
BC-05 sandwich ELISA assay that specifically detectsspectively, in N2a lines that stably coexpress human
APP and human wild-type PS1 (Figure 1A, lanes 2 and Ab1–40 and Ab1–42(43), respectively (Suzuki et al.,1994;
Gravina et al., 1995; Scheuner et al., 1996). In view of3). Both the full-length PS1 and z17 kDa human PS1
derivative were detected in lines that stably coexpress the differing steady-state levels of human APP and hu-
man PS1 (or PS1 variants) and clonal variability in Abthe M146L (Figure 1A, lanes 4–7) or A246E (Figure 1A,
lanes 8 and 9) PS1 variants. These results demonstrate secretion, we chose to calculate the ratio of Ab1–42(43)
to Ab1–40 (i.e., the Ab42/40 ratio), instead of comparingthat these FAD-linked PS1 variants are efficiently pro-
cessed. In lines expressing the DE9 PS1 variant (Figure the absolute levels of Ab for each sample (Table 1). The
Elevated Ab1–42(43)/Ab1–40 Ratio
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Figure 1. PS1 Expression in Stable N2a Cells
Mouse N2a neuroblastoma cells were cotrans-
fectedwith expression plasmidsencodingwild-
type human APP-695 and wild-type human
PS1, PS1M146L, PS1A246E, or PS1DE9. Deter-
gent lysates (25 mg) were fractionated by SDS–-
polyacrylamide gel electrophoresis (PAGE)
and expression of PS1 was analyzed by im-
munoblottingwith PS1Loopantiserum (A) and
N-terminal Ab14 antiserum (B). Note that
aPS1Loop antiserum detects mouse PS1 at
about 40% efficiency of human PS1 (Thina-
karan et al., 1996). The positions of full-length
PS1 (FL), C-terminal and N-terminal PS1-
derived fragments (CTF and NTF, respec-
tively) are marked.
statistical significance was calculated using the nonpar- (0.154 6 .011 versus 0.098 6 .004, P 5 0.0102). Signifi-
cantly, the Ab42/40 ratios were higher in seven linesametric Mann-Whitney test. The Ab42/40 ratio in me-
dium of N2a lines expressing human APP alone, or in that expressed mutant PS1 (i.e., ML.2, ML.11, ML.4,
AE.23, AE.29, DE9.23, and DE9.21) at levels lower than,combination with wild-type human PS1, were compara-
ble (0.093 6 0.004 and 0.100 6 0.006, respectively). In or equivalent to, wild-type human PS1 in lines wt.3 and
wt.25 (0.128 6 0.004 versus 0.1 6 0.006, respectively;this regard, despite an z3-fold difference in the level of
human PS1 expression between lines wt.3 and wt.25 P 5 .0405). Interestingly, and for reasons not presently
clear, an z2-fold increase in expression of PS1DE9 in(Figures 1A and 1B, lanes 2 and 3), the Ab42/40 ratio in
these lines were quite comparable (0.094 6 0.006 and line DE9.9 compared with line DE9.21 (Figure 1A, lanes
10 and 11) resulted in a remarkable increase in the Ab42/0.106 6 0.011, respectively). However, stable lines ex-
pressing the M146L (Figures 1A and 1B, lanes 4–7), 40 ratio (0.199 6 0.004 versus 0.113 6 0.003). However,
further increases in the expression of the DE9 PS1 vari-A246E (Figures1A and 1B, lanes 8 and 9), or DE9 (Figures
1A and 1B, lanes 10–14) PS1 variants exhibited signifi- ant (Figure 1A, lanes 13 and 14) did not significantly
elevate the Ab42/40 ratio. Notably, the Ab42/40 ratio forcantly higher Ab42/40 ratios relative to wild-type lines
Figure 2. APP Expression in Stable N2a Cells
Detergent lysates (25 mg) prepared from un-
transfected N2a cells (N2a) and stable N2a
lines coexpressing human wild-type APP and
human PS1 polypeptides (wild-type PS1,
PS1M146L, A246E, orPS1DE9) were fraction-
ated by SDS–PAGE, and APP expression was
examined by immunoblotting with CT15 anti-
serum.
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created by replacing sequences encoding the Ab do-Table 1. Ratio of Ab1–42(43)/Ab1–40 Species Secreted by
Stable N2a Lines main of murine APP with the cognate sequences from
Hu APP, thus allowing examination of the influence ofRatio of
PS1 on human Ab. All transgenes were transcriptionallyAb1–42(43)/Ab1–40 Number of
dependent upon the murine prion promoter (MoPrP)N2a Line Mean 6 SEM Experiments
vector (Thinakaran et al., 1996). The levels of human AbWild-Type PS1 Lines
peptides in brain homogenates of transgenic animals
(0.098 6 0.004) were determined using a quantitative sandwich ELISA
assay, described above (Suzuki et al., 1994; Gravina etwt.7 0.093 6 0.004 4
wt.3 0.094 6 0.003 6 al., 1995; Scheuner et al., 1996).
wt.25 0.1060 6 0.011 6 Our previous investigations of PS1 expression in
PS1M146L Lines transgenic mice revealed that 43 kDa human PS1 is
proteolytically processed to generate z27 kDa N-termi-(0.143 6 0.019; P 5 0.0339a)
nal and z17 kDa C-terminal derivatives, which accumu-
ML.2 0.130 6 0.007 6 late to equivalent levels (Thinakaran et al., 1996). We
ML.11 0.131 6 0.009 6
examined the expression of the A246E PS1 variant inML.4 0.113 6 0.007 6
total SDS extracts of brains of transgenic mice withML.10 0.200 6 0.011 6
Ab14, a polyclonal serum specific for amino acids 3–15
PS1A246E Lines
of human and mouse PS1 and mAb N-term, a mono-
(0.135 (mean)) clonal antibody (mAb) specific for PS1 N-terminal epi-
topes (see below; Figure 3B). We show that 43 kDa PS1-AE.23 0.133 6 0.012 6
AE.29 0.138 6 0.016 6 A246E is cleaved to generate 27 kDaderivatives (Figures
3A and 3B, lanes 5 and 6), which comigrated withPS1DE9 Lines
N-terminal derivatives from human PS1 (Figure 3A, lanes
(0.170 6 0.019; P 5 0.0253a) 7 and 8). Notably, the A246E mutation is predicted to
DE9.23 0.137 6 0.005 6 reside in the 27 kDa N-terminal fragment. Parallel immu-
DE9.21 0.113 6 0.004 6 noblot studies with antiserum to sequences in the loop
DE9.9 0.199 6 0.004 4 domain of PS1 (Thinakaran et al., 1996) demonstrated
DE9.14 0.195 6 0.010 6
the presence of C-terminal 17 kDa derivatives generated
DE9.18 0.206 6 0.011 6
from the mutant PS1 polypeptide (data not shown).
All mutant lines average 0.154 6 0.011; P 5 0.0102. Thus, the A246E mutation does not conspicuously alter
a P values were calculated by nonparametric Mann-Whitney test.
proteolytic processing of the PS1 variant in brain, con-
sistent with our findings in stably transfected N2a cells
(see above).
In the brains of mice from wild-type PS1 mice (linea line expressing the highest levels of the M146L variant
S8-4), we observed high levels of accumulated full-(ML.10; Figure 1, lane 7) was 0.200 6 0.001. In this
length 43 kDa species. In earlier studies, we demon-instance, high levels of full-length M146L PS1 also accu-
strated that human PS1 mRNA is highly overexpressedmulated.
in the brains of line S8-4, and we argued that accumula-At present, the relativecontributions of full-length mu-
tion of full-length human PS1 is the result of high syn-tant PS1 or its fragments to Ab42/40 production isunset-
thetic rates of transgene-encoded mRNAs (Thinakarantled. We reported that the preponderant PS1 species in
et al., 1996). In those studies, we also documented thatvivo are its endoproteolytic derivatives (Thinakaran et
the levels of accumulated N-terminal human PS1 frag-al., 1996); in stably transfected cells, it is conceivable
ments in brains of line S8-4 were indistinguishable fromthat accumulated full-length mutant PS1 may elevate
the levels of accumulated N-terminal fragments inbrainsthe Ab42/40 ratios in a manner that is nonphysiologic.
of independent lines of mice expressing human PS1However, it is quite clear that in lines expressing different
mRNA at levels z10- to 20-fold lower than mRNA in linemutant PS1 with nearly undetectable levels of accumu-
S8-4 (Thinakaran et al., 1996). From these analyses, welated full-length mutant PS1 (lines ML.2, AE.23, and
concluded that accumulation of thePS1 endoproteolyticDE9.23), the Ab42/40 ratio averaged 0.133 compared
derivatives is highly regulated and saturable. In contrastwith wild-type PS1-expressing lines that exhibited an
to line S8-4, very little full-length A246E PS1 accumu-Ab42/40 ratio of 0.1, despite the accumulation of full-
lated in the brains of line N5, consistent with Northernlength wild-type PS1.
blot analyses, which demonstrated that brain mRNA
levels in line N-5 are z3- to 5-fold lower than in line
Expression of Human PS1 and Human APP S8-4 (data not shown). Interestingly, the levels of accu-
in Transgenic Mice mulated N-terminal human PS1 fragments in brains of
To examine the influence of mutant PS1 on Ab42/40 lines N5 and S8-4 are quite comparable, despite the
ratios in an in vivo setting, we examined Ab42/40 ratios accumulation of full-length wild-type PS1 in line S8-4.
in the brains of transgenic mice expressing wild-type or Total APP levels in detergent extracts from the brains
mutant PS1. Mice expressing either wild-type Hu PS1 of the APPswe transgenic mice and mice coexpressing
or the FAD-linked A246E PS1 variant were mated to APPswe and Hu PS1 were examined by immunoblotting
transgenic mice expressing a chimeric Mo/Hu APP- with CT15, an APP C-terminal specific antiserum; the
CT-15 epitope is conserved in human and murine APP.695swe (APPswe) polypeptide. The APPswe cDNA was
Elevated Ab1–42(43)/Ab1–40 Ratio
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Figure 4. Expression of Mo/Hu APP-695swe in Transgenic Mice
Coexpressing Wild-Type and Mutant Human PS1
Total SDS extractsof brain protein were analyzedby immunoblotting
with CT15, an antibody that recognizes both murineand human APP.
Mice harboring the APPswe transgene show an z2 fold increase in
APP immunoreactivity. Lanes 1 and 2, nontransgenic mice; lanes 3
and 4, transgenic mice harboring APPswe transgenes alone; lanes
5 and 6, transgenic mice harboring APPswe and mutant human PS1
transgenes; lanes 7 and 8, transgenic mice harboring APPswe and
wild-type human PS1 transgenes.
sandwich ELISA assays, described above (Suzuki et al.,
1994; Gravina et al., 1995; Scheuner et al., 1996). Al-
though the absolute levels of Ab1–40 and Ab1–42(43)
in the brains of transgenic mice varied considerably,
coexpression of mutant PS1 with APPswe dispropor-
tionately elevated the concentration of Ab1–42(43) rela-
tive to Ab1–40 (Figure 5); the Ab42/40 ratio shifted from a
mean of 0.215 (SE 5 0.011) in littermate mice expressing
APPswe alone (Group A) to a mean of .305 (SE 5 0.014)
in mice expressing both APPswe and mutant PS1. Im-
Figure 3. Expression of Wild-Type andMutant Hu PS1 in Transgenic portantly, the Ab42/40 ratios in mice coexpressing mu-
Mice tant PS1 and APPswe did not overlap with those for
The cortex, hippocampus, and thalamus of brains from 2- to mice expressing APPswe alone; nonparametric Mann-
3-month-old transgenic and nontransgenic littermates were homog- Whitney statistical analyses revealed that the difference
enized as described in Experimental Procedures.
between the two groups was highly significant (P 5(A) and (B) We analyzed 50 mg of brain protein by immunoblot with
0.006). Because we observed significant variability inN-terminal antibodies Ab14 and mAb N-term. Bound primary anti-
absolute levels of total Ab42/40 in the cohort of APPswebodies were revealed by [125I]-protein A (primary mAb required prior
to incubation with rabbit antiserum to mouse IgG). The mAb N-term littermates (Group A), we repeated the analyses on a
specifically recognizes human PS1. cohort of APPswe animals alone (APPswe B6 n1 genera-
(C) A Coomassie-stained gel, run in parallel, demonstrates equal tion; see Experimental Procedures), which were aged 7
loading of brain protein extracts. Lanes 1 and 2, nontransgenic mice;
months (Group B). The ratios of Ab42/40 in the brainslanes 3 and 4, transgenic mice harboring APPswe transgenes alone;
from the two groups of APPswe mice (Groups A and B)lanes5 and6, transgenic mice harboring APPswe and mutant human
were very similar (0.215 and 0.212, respectively). Non-PS1 transgenes; lanes 7 and 8, transgenic mice harboring APPswe
and wild-type human PS1 transgenes. parametric Mann-Whitney analyses revealed that the
50% increase in the Ab42/40 ratio in the brains of mice
expressing both APPswe and mutant Hu PS1 as com-
pared with mice expressing APPswe alone (Groups AWe observed an increase in the levels of accumulated
100–110 kDa APP (Figure 4, lanes 3–8) compared with and B) was highly significant (P 5 0.001). Thus, despite
the variability in total Ab levels, the effects of mutantlittermates lacking transgenes (Figure 4, lanes 1 and 2).
Phosphorimaging analysis of CT-15 immunoblots indi- Hu PS1 were sufficiently robust to cause detectable,
and highly statistically significant, increases in the Ab42/cated an z2-fold increase in APP levels in mice harbor-
ing the APPswe transgene. Parallel analyses with mAb 40 ratio.
To examine the effects of human wild-type PS1 on6E10, specific for human Ab sequences (Kim et al., 1988,
1990; Hsiao et al., 1995), confirmed the presence of Ab42/40 ratios, we examined the brains of two mice
coexpressing APPswe and wild-type human PS1. Wehumanized Ab domains in the APPswe polypeptides
(data not shown). observed that the Ab42/40 ratio in these animals was
0.192, a value not statistically different from the mice
expressing APPswe alone (Figure 5). Thus, increasingAb Levels in Brains of Transgenic Mice
Coexpressing Human PS1 and Human APP PS1 expression alone is not sufficient to alter the Ab42/
40 ratio. Moreover, a significant shift in the Ab42/40 ratioLevels of Ab were measured in homogenates of brains
from 2- to 3-month-old transgenic mice by quantitative (P 5 0.05) was observed when we compared values for
Neuron
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FAD-linked mutations cause AD by increasing the extra-
cellular concentration of highly amyloidogenic Ab1–
42(43) species, thus fostering Ab amyloid deposition in
the brain.
To examine directly the influences of wild-type and
mutant PS1 on Ab1–40 and Ab1–42(43) production, we
generated stable mouse neuroblastoma (N2a) cell lines
that constitutively express human APP in combination
with human PS1 or FAD-linked PS1 variants. We ex-
tended these investigations to analyze the Ab1–42(43)
to Ab1–40 ratio in the CNS of transgenic mice that ex-
press a chimeric APP (APPswe) in combination with
wild-type PS1 or the FAD-linked A246E PS1 variant.
Our findings provide the first demonstration of a bona
fide effect of wild-type and mutant PS1 on Ab42(43)
production in vitro and in vivo and offer important in-
sights into the pathogenetic mechanism of PS1-linked
FAD. First, we document that the ratio of Ab1–42(43)/
Ab1–40 in the medium of independent cell lines express-
ing variable levels of either the A246E, the M146L, or
DE9 PS1 variants is uniformly elevated compared with
medium of cells expressing wild-type PS1. In these stud-
ies, elevated extracellular Ab42(43) accumulation, medi-
ated by mutant PS1, occurred in independent lines that
express the M146L, A246E, or DE9 variants at levels
lower than, or comparable with, lines expressing human
wild-type PS1. Second, we document that the ratio of
Ab1–42(43) to Ab1–40 in the brains of young transgenic
animals coexpressing APPswe and mutant PS1 is ele-
vated by 50% compared with transgenic mice express-
ing APPswe alone or transgenic mice coexpressing
Figure 5. Scatter Plot of Ab1–42(43) to Ab1–40 Ratios
wild-type Hu PS1 and APPswe. At this time, amyloid
Data on Ab1–42(43) to Ab1–40 ratios are displayed to illustrate the
deposition and associated neuropathological abnor-lack of overlap between values in the APPswe 1 mutant human
malites have not been detected in the brains of olderPS1 transgenics versus APPswe alone and APPswe 1 wild-type
mice expressing either APPswe alone (14 months), mu-human PS1 mice. Horizontal bars mark the average value for Ab1–
42(43) to Ab1–40 ratios. Asterisk: this average value is significantly tant PS1 alone (8 months), or young animals coexpress-
higher than the average value for APPswe mice (P 5 0.001) and ing APPswe and mutant PS1 (D. R. B. and M. K. L.,
APPswe 3 wild-type human PS1 mice (P 5 0.05). unpublished data). Hence, the alterations in Ab1–42(43)/
Ab1–40 ratios detected in the brains of our young ani-
mals coexpressing APPswe and mutant PS1 are not the
mice coexpressing wild-type PS1 and APPswe (0.192) consequence of pathogenic processes, but rather are
and mice coexpressing mutant PS1and APPswe (0.305). indicative of fundamental changes in the processing of
The higher level of transgene expression in wild-type APP. Collectively, the data obtained from stably trans-
PS1 mice (line S8-4) underscores the significance of fected cells and brains of transgenic mice provide com-
these observations and leads us to conclude that only pelling support for the view that one mechanism by
mutant Hu PS1 influences APP processing in a manner which mutant PS1 causes AD is the acquisition (or en-
that enhances Ab1–42(43) production. hancement) of property(ies) that influence APP pro-
cessing in a manner that leads to increased extracellular
Discussion concentrations of Ab1–42(43).
Our findings are notable in view of several lines of
Mutations in PS1 and PS2 cosegregate with the majority evidence in support of the idea that Ab1–42(43) plays a
of pedigrees with early-onset FAD, but the molecular critical role in the pathogenesis of AD: first, biophysical
mechanism(s) by which FAD-linked PS1 and PS2 vari- studies demonstrate that Ab1–42 has rapid nucleation
ants cause AD are unclear. The absence of nonsense and aggregation kinetics (Jarrett and Lansbury, 1993);
or frameshift mutations leading to truncated PS1/PS2 second, mass spectrometric analyses of purified amy-
support the notion that AD is caused not by the loss, loid plaques revealed that Ab1–42 is the principal com-
but by the gain, of deleterious properties of the mutant ponent of amyloid deposits (Roher et al., 1993); third,
polypeptides. In this regard, recent studies indicate that cells expressing FAD-linked APP with missense muta-
conditioned medium from fibroblasts or plasma of af- tions at position 717 (of APP-770) secrete high levels of
fected members of pedigrees with PS1/PS2-linked mu- Ab1–42(43) (Suzuki et al., 1994); and fourth, biochemical
tations show a significant increase in the ratio of Ab1– and immunocytochemical studies of brains from pa-
42(43)/Ab1–40 relative to unaffected family members tients with AD (Iwatsubo et al., 1994; Gravina et al., 1995)
and Down’s Syndrome (Iwatsubo et al., 1995; Lemere(Scheuner et al., 1996). These data suggest that the
Elevated Ab1–42(43)/Ab1–40 Ratio
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and bound radioactivity was quantified by phosphorimaging (Molec-et al., 1996a) using end-specific antibodies revealed that
ular Dynamics, Sunnyvale, CA).Ab species terminating at residue 42(43) occur early
and selectively in both diffuse and compact amyloid
Generation of Stable Cell Lines Expressing PS1 and APP
plaques. Significantly, recent studies (Lemere et al., Stable mouse N2a neuroblastoma cells were generated by cotrans-
1996b) have demonstrated abundant Ab42(43) deposi- fecting 5 mg MoPrP. PS1 expression plasmids encoding human
wild-type PS1, PS1M146L, PS1A246E, or PS1DE9, with 0.5 mg oftion in the cerebral cortex and cerebellum of individuals
cDNA encoding human wild-type APP-695 in a CMV expressionwith a PS1-linked E280A mutation with amyloid burdens
vector, pCB6 (Lo et al., 1994). Expression of human PS1 in G418-that far exceeds that described for individuals homozy-
resistant lines was determined by Western blot analysis with poly-gous for apoE4 alleles (Roses, 1994; Hyman et al., 1995).
clonal aPS1Loop and Ab14 antisera (Thinakaran et al., 1996). Ex-
All of these lines of evidence indicate that Ab1–42(43) pression of human APP was determined by Western blot analysis
is a critical peptide in the pathogenesis of amyloid depo- with CT15 antiserum. One N2a line expressing APP and undetect-
able levels of human PS1 (wt.7), two wild-type PS1 lines (wt.3 andsition. These converging lines of evidence, in conjunc-
wt.25), four PS1M146L lines (ML.2, ML.4, ML.10, and ML.11), twotion with our demonstration that mutant PS1 influences
PS1A246E lines (AE.23 and AE.29), and five PS1DE9 lines (DE9.9,APP processing in vitro and in vivo, are consistent with
DE9.14, DE9.18, DE9.21, and DE9.29) were used in this study.
the hypothesis that elevated extracellular concentra-
tions of amyloidogenic Ab1–42(43) peptides precipitate Generation of Transgenic Mice
disease in PS1-linked FAD. Transgenic mice expressing wild-type Hu PS1 were previously de-
scribed (Thinakaran et al., 1996). In the present study, we used a
line of transgenic mice expressing very high levels of wild-type Hu
Experimental Procedures PS1 (line S8-4) (Thinakaran et al., 1996). To generate transgenic
mice expressing the A246E PS1 variant, we injected pronuclei with
linealized expression plasmid, MoPrP. A246E, described above. AllGeneration of PS1 Expression Vectors
Hu PS1 transgenic mice were maintained as C3H/HeJ 3 C57BL/6JA cDNA-encoding human PS1 was generated as described (Slunt et
hybrids.al., 1995). PS1 cDNA encoding the A246E substitution was generated
To generate cDNA encoding Mo/Hu APP-695swe, a PCR-basedby RT–PCR of cytoplasmic RNA isolated from skin fibroblasts of a
strategy was utilized in which the oligonucleotide primers encodedpatient harboringthe A246Emutation (NIA Cell Repository #AG06848B)
the “Swedish” missense mutations and contained appropriate re-using the primer pair, hAD3-ATG-Kpn (GGGGTACCATGACAGAGTT
striction endonuclease sites to allow for the construction of chimericACCTGCAC) and hAD3-R-39UTR (CCGGGATCCATGGGATTCTAAC
APP. The cDNA were sequenced prior to insertion into the MoPrP.CGC). PCR product was digested with Asp-718 and BamHI, and z1.4
Xho vector. Mice harboring the APPswe transgene were initiallykB PS1 cDNA was gel purified and ligated to Bluescript KS1 vector
generated in F2 hybrids of C3H/HeJ 3 C57BL/6J mice. The F3(Stratagene, La Jolla, CA) previously digested with Asp-718 and BamHI,
progeny of these matings were subsequently mated to C57BL/6Jto generate phPS1A246E. The cDNA were sequenced in their entirety
for one generation (APPswe B6n1) before mating to mice harboringusing a Sequenase (U. S. B, Cleveland, OH). To generate human PS1
PS1 transgenes (all of which were F3 progeny of C3H/HeJ 3 C57BL/cDNA encoding the M146L substitution, we used a four-way PCR
6J matings).strategy with two primer pairs and full-length PS1 cDNA as template.
The primer pairs for the initial PCR reactions were hAD3-M146LF (GTC
Analysis of Ab1–40 and Ab1–42(43) SecretedATTGTTGTCCTGACTATCCTCCTG)/hAD3-R284 (GAGGAGTAAATGA
by Stable N2a PS1/APP LinesGAGCTGG) and hAD3-M146LR (CAGGAGGATAGTCAGGACAACAAT
Stable N2a lines were plated 1 3 106 cells/60 mm dish and main-GAC)/hAD3-237F (CAGGTGGTGGAGCAAGATG). PCR products from
tained in 1:1 OptiMEM (GIBCO-BRL, Bethesda, MD) and Dulbecco’seach reaction were gel purified, combined, and subject to a second
modified Eagle’s medium supplemented with 10% fetal bovine se-round of PCR with primers hAD3-237F and hAD3-R284. The resulting
rum. The following day, culture medium was replaced with freshproduct was digested with KasI and PflMI and an z300 bp gel-
medium containing 10 mM butyrate (to induce transcription of thepurified fragment was ligated to KasI/PflM1-digested phPS1 to gen-
CMV promoter-driven human APP cDNA) (Loet al., 1994). The condi-erate phPS1M146L. The inserts and junctions weresequenced using
tioned medium was collected 24 hr later and stored frozen at 2708C.Sequenase (U. S. B, Cleveland, OH). The strategy for generating
The samples were coded in order to facilitate a blinded comparison.cDNA encoding PS1 lacking exon 9 (amino acids 290–319) was
Aliquots of conditioned medium were analyzed by BAN-50/BA-27described previously (Thinakaran et al., 1996). Sequences encoding
or BAN-50/BC-05 sandwich ELISA assays essentially as previouslyPS1 variants were subcloned downstream of mouse prion promoter
described (Suzuki et al., 1994; Scheuner et al., 1996) to measurein plasmid MoPrP. Xho (Thinakaran et al., 1996), to generate MoPrP.
Ab1–40 and Ab1–42(43), respectively.PS1 expression plasmids.
Analysis of Ab1–40 and Ab1–42(43) in Brain Tissue
Antibodies Approximately 150 mg of tissue was dounce homogenized (6
Two antibodies directed against N-terminal epitopes of PS1 were strokes) in 1 ml of 70% formic acid. Homogenates were centrifuged
used in this study: Ab14 is a polyclonal serum specific for amino at 100,000 3 g for 1 hr to remove particulate material. The superna-
acids 3–15 of human and mouse PS1 (Thinakaran et al., 1996), and tant was recovered and neutralized with a 20-fold dilution in 1 M
mAb N-term is a concentrated cell culture supernatant from a rat Tris base. Following neutralization, 100 ml of the sample was mixed
myeloma primed with a chimeric protein consisting of the N-terminal with 50 ml of EC buffer (0.02 M sodium phosphate, 0.2 mM EDTA,
80 amino acids of human PS1 fused to bacterial glutathione 0.4 M NaCl, 0.2% BSA, 0.05% CHAPS, 0.4% Block-Ace, 0.05%
S-transferase. aPS1Loop, an antiserum that specifically reacts with sodium azide [pH 7.0]) and analyzed directly using the BAN-50/
epitopes in the hydrophilic loop domain of PS1 (amino acids 263– BA27 and BAN-50/BC05 sandwichELISA system(Suzuki et al., 1994;
407) (Thinakaran et al., 1996) was used to detect PS1 C-terminal Gravina et al., 1995; Hsiao et al., 1995; Scheuner et al., 1996). The
derivatives. values obtained were calculated by comparison with the absorban-
For Western blot analysis, detergent lysates were prepared from ces obtained from a standard curve of synthetic Ab1–40 and Ab1–42
cells and transgenic mouse brains as described previously (Thina- (Bachem, King of Prussia, PA), adjusted for sample dilution, and
karan et al., 1996). The steady-state expression of PS1 and APP in converted to pmols/g wet weight tissue.
cultured cells and mouse brain was examined by Western blot analy-
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